We are excited to announce that we closed our $26M Series A this summer with the support from amazing investors who share our passion and drive to improve available treatment options for pregnancy, globally! Read more in our recent press release below. AXA Investment Managers, Laerdal Million Lives Fund, Laborie, RH Capital, Avestria Ventures, March of Dimes, First Avenue Ventures #maternalhealth #birthinnovation #pretermbirth #womenshealth
Novocuff, Inc.
医疗设备制造业
Novocuff is a medical device company dedicated to improving outcomes for pregnancies affected by PPROM or short cervix.
关于我们
Novocuff, Inc. is a medical device company dedicated to improving pregnancy outcomes and reducing the risk of preterm birth.
- 网站
-
https://www.novocuff.com
Novocuff, Inc.的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 2-10 人
- 类型
- 私人持股
Novocuff, Inc.员工
动态
-
Fellowship alum Amelia Degenkolb and her co-founder Donald Lee snag $26m in funding to advance a device intended to prevent preterm birth and improve maternal health. Well done!!! A great milestone that will pave the way for other startups in women's health! Novocuff, Inc. #womenshealth #healthcare
?? ?? ?? CONGRATS! Fogarty company-in-development Novocuff, Inc., which is dedicated to improving pregnancy outcomes, has raised an oversubscribed $26 million Series A funding round. Led by co-founder/CEO Amelia Degenkolb and co-founder/COO Donald Lee, Novocuff is working to reduce preterm births, the leading cause of infant mortality globally, caused by complications like preterm premature rupture of membranes (PPROM) and cervical shortening. The company has developed a novel solution intended to stabilize and close the cervix and plans to commence a multi-center U.S. pivotal clinical trial in early 2025. Novocuff is participating in Fogarty's Company Accelerator Program, a short term program designed to help early stage companies achieve specific objectives. Learn more: https://lnkd.in/gbK4EVJU #womenshealth
-
Becca Shmukler and the Laerdal Million Lives Fund (LMLF) team supported Donald Lee and me at Novocuff, Inc. from the time we were first engaged in 2023. LMLF joined our seed round and we are grateful for their continued support and investment in our Series A raise. Thank you for the partnership. We are committed to shared goals of improved health of families near and far. Energetically, we face the road ahead together! Jeff Trost, Rhiya Pau
As I return to work after my second maternity leave and enter a life stage where many people close to me are navigating fertility, pregnancy, and parenting journeys that are often challenging and complex, I could not be more proud to share the Laerdal Million Lives Fund’s latest investment in Novocuff, Inc. Novocuff’s mission is to dramatically elevate the standard of care for women at risk for preterm birth and their infants, to ultimately reduce the morbidity and mortality burden associated with prematurity. We are thrilled to support Amelia Degenkolb and Donald Lee toward this ambitious goal to help save the littlest lives alongside a world-class syndicate from AXA Investment Managers, RH Capital, March of Dimes, Laborie, and Avestria Ventures. https://lnkd.in/esbcAR4Q
Novocuff Raises $26 Million in Oversubscribed Series A Funding to Advance Technology Aimed at Reducing Preterm Births
finance.yahoo.com
-
In June 2022, I reached out to Curt LaBelle at AXA Investment Managers #AXAIMAlts because I knew that we shared a desire to advance innovations that can make a positive global impact. Donald Lee and I had been working together at Novocuff, Inc. for almost a year and I believed we were onto something that fit this description. I knew we were too early for AXA IM at that moment, but we got to meet the team and bring them along on our journey till we were ready to raise our Series A. We are so grateful to AXA IM and their team for leading our series A with a momentous investment that will fuel the next big endeavors in our journey! Lilly deSouza Burr, Cameron Irby
#AXAIMAlts is pleased to announce a $14 million lead investment as part of a $26 million financing round into Novocuff, Inc., a women’s #health medical device company dedicated to improving #pregnancy outcomes and reducing preterm births. The investment, through AXA IM Alts’ Global #Healthcare #PrivateEquity Strategy, will facilitate a multi-site pivotal clinical trial across the #UnitedStates, marketing submission to the U.S. Food and Drug Administration, and support Novocuff’s growth ambitions and business operations into the early commercialization of the Novocuff Cervical Control System. The Novocuff CCS has been designed to improve pregnancy outcomes and reduce preterm birth, with the first indication of PPROM (preterm premature rupture of membranes, or “water breaking”). Preterm birth affects over 13 million babies globally each year and continues to be the leading cause of death among children under five years of age. For babies that survive, preterm birth requires expensive hospital stays and may lead to life-long health issues. The economic impact of preterm births is significant – exceeding $25 billion annually. There are currently no reliable therapeutic or device interventions cleared for retaining amniotic fluid or extending latency following PPROM. Novocuff is pursuing a novel approach in its effort to provide a solution to these critical conditions. The company’s mission is to transform the standard of care and improve pregnancy outcomes globally for women and their babies. The Novocuff CCS is designed to be a minimally invasive, non-surgical device that does not require special storage conditions. AXA IM Alts’ Global Healthcare Private Equity Strategy seeks to invest in companies with innovative and affordable solutions to global health challenges. The Strategy includes high-volume markets, where demand for new products has the potential to benefit from rapid growth in healthcare spending and population growth. This investment into Novocuff represents AXA IM Alts’ efforts to positively contribute to the United Nation’s established target to reduce newborn mortality to less than 12 deaths per 1000 live births and is directly aligned to Sustainable Development Goal 3: Good Health and Well-Being. AXA IM Alts has over 20 years’ experience of investing in private equity impact and healthcare, with the women’s health sector being a key focus for the Platform. This latest investment represents AXA IM Alts’ commitment within this space and its dedicated origination channels. Congrats Curt LaBelle Jonathan Dean Alexandre Martin-Min for this great addition to our portfolio! https://lnkd.in/eaJmu8mV
Novocuff Raises $26 Million in Oversubscribed Series A Funding to Advance Technology Aimed at Reducing Preterm Births
morningstar.com
-
We are pleased to be partnering with RH Capital. They have a track record of supporting women's and maternal health innovation that have already improved available therapies for families and their clinicians. Their investment in our series A propels Novocuff, Inc. into the next stages of our journey to tackle the global problem of preterm birth. Onward and upward! Elizabeth Bailey, Sandie Eltringham, Alice Zheng
Congratulations Novocuff, Inc.! RH Capital invested in Novocuff's Series A round, supporting the company's mission to improve pregnancy outcomes and reduce the risk of preterm birth.?Novocuff is developing an innovative medical device to address the complexities of?PPROM and short cervix, with the goal of extending pregnancy. AXA Investment Managers, through its Global Healthcare Private Equity Strategy, led the round?alongside significant participation from Laerdal Million Lives Fund, in addition to support from existing and new investors Laborie, Avestria Ventures and March of Dimes. We are excited to be on this journey with you Amelia Degenkolb, Donald Lee and team! Full story in Femtech Insider: CC: Alice Zheng, Stasia Obremskey, Elizabeth Bailey, Kathrin Folkendt
Novocuff Secures $26M in Series A Funding to Advance Preterm Birth Prevention Technology
https://femtechinsider.com
-
If you are part of the innovation ecosystem for women's or maternal health, you have likely met Tracy Dooley MD and Linda Greub, CFA, MBA with Avestria Ventures. The Novocuff, Inc. team is grateful to be supported by an investment from Avestria in our recent Series A. We are excited to be taking the next steps of our journey with such a passionate and dedicated fund!
As I return to work after my second maternity leave and enter a life stage where many people close to me are navigating fertility, pregnancy, and parenting journeys that are often challenging and complex, I could not be more proud to share the Laerdal Million Lives Fund’s latest investment in Novocuff, Inc. Novocuff’s mission is to dramatically elevate the standard of care for women at risk for preterm birth and their infants, to ultimately reduce the morbidity and mortality burden associated with prematurity. We are thrilled to support Amelia Degenkolb and Donald Lee toward this ambitious goal to help save the littlest lives alongside a world-class syndicate from AXA Investment Managers, RH Capital, March of Dimes, Laborie, and Avestria Ventures. https://lnkd.in/esbcAR4Q
Novocuff Raises $26 Million in Oversubscribed Series A Funding to Advance Technology Aimed at Reducing Preterm Births
finance.yahoo.com
-
The Novocuff, Inc. Team is honored to be a portfolio company with the March of Dimes Investment Fund! Eric Schaefer has been a thoughtful partner and has connected us with clinician thoughtleaders as we pursue our goal of reducing the risk of and morbidities associated with preterm birth. We look forward to taking the next steps of our journey together.
We are excited to announce Novocuff, Inc. as our latest portfolio company for our Innovation Fund, a venture philanthropy initiative that invests in early-stage companies to address the most pressing maternal and infant health challenges to improve outcomes for moms’ and babies. Novocuff has developed a medical device to address the problems associated with the conditions of PPROM and short cervix, with the goal of extending pregnancy. Learn more about the March of Dimes investment in Novocuff: https://lnkd.in/gbK4EVJU
-
Novocuff, Inc. is excited to have the support of Laborie and Patricia Industries in our recent Series A! Nikki Bruce and the Laborie Team share our commitment to improve available treatment options to help mothers and newborns go home healthy. We look forward to the next steps of our journey, working to address preterm birth caused by PPROM and cervical shortening. Eric Chehab, Michael Daily, Yuriy Prilutskiy
We are pleased to announce that Laborie is investing in Novocuff, Inc. an early-stage medical technology that is developing a device to improve pregnancy outcomes and reduce preterm births. "We believe Novocuff's device has the potential to address pregnancy complications that often result in preterm birth, and our investment underscores our commitment to improving patient outcomes," said Nikki Bruce, Vice President and General Manager of Laborie's OB Business Unit. Read the press release: https://lnkd.in/eCnxG8qb #ForDignityForLife #Laborie
-
We are excited to announce that we closed our $26M Series A this summer with the support from amazing investors who share our passion and drive to improve available treatment options for pregnancy, globally! Read more in our recent press release below. AXA Investment Managers, Laerdal Million Lives Fund, Laborie, RH Capital, Avestria Ventures, March of Dimes, First Avenue Ventures #maternalhealth #birthinnovation #pretermbirth #womenshealth
Novocuff Raises $26 Million in Oversubscribed Series A Funding to Advance Technology Aimed at Reducing Preterm Births
businesswire.com
-
We are so excited and grateful return to Fogarty Innovation! An amazing medical device incubator with seasoned experts and fellow innovators! #maternalhealth #innovation #womenshealth Donald Lee, Amelia Degenkolb
"We know that an effective treatment will not only bring hope to women and families who need it but will also contribute to the body of evidence that that demonstrates how significant the opportunity for innovation is in maternal and women’s health in general." - Donald Lee, COO of Novocuff, a #womenshealth start up that has joined Fogarty Innovation. https://lnkd.in/gRbtgz6p #Innovation #medtech
Novocuff Joins FI to Help Prevent Preterm Birth? - Fogarty Innovation
https://www.fogartyinnovation.org